Notch signaling: an emerging therapeutic target for cancer treatment

Cancer Lett. 2015 Dec 1;369(1):20-7. doi: 10.1016/j.canlet.2015.07.048. Epub 2015 Sep 1.

Abstract

The Notch pathway is involved in cell proliferation, differentiation and survival. The Notch signaling pathway is one of the most commonly activated signaling pathways in cancer. Alterations include activating mutations and amplification of the Notch pathway, which play key roles in the progression of cancer. Accumulating evidence suggests that the pharmacological inhibition of this pathway can overcome chemoresistance. Efforts have been taken to develop Notch inhibitors as a single agent or in combination with clinically used chemotherapeutics to treat cancer. Some Notch inhibitors have been demonstrated to have therapeutic efficacy in preclinical studies. This review summarizes the recent studies and clinical evaluations of the Notch inhibitors in cancer.

Keywords: Clinical trials; Notch signaling; Targeted therapy; γ-Secretase inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Receptors, Notch / antagonists & inhibitors
  • Receptors, Notch / physiology*
  • Signal Transduction*

Substances

  • Antineoplastic Agents
  • Receptors, Notch